Incyte Corp
Closed
SectorHealthcare
103.18 2.37
Overview
Share price change
24h
Min
100.6
Max
104.12
Income | 4.1M 303M |
|---|---|
Sales | -234M 1.3B |
P/E Sector Avg | 14.215 49.888 |
EPS | 1.81 |
Profit margin | 23.834 |
Employees | 2,844 |
EBITDA | -47M 368M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +9.36% upside |
Next Earnings | 28 Jul 2026 |
|---|
Market Cap | 1.1B 20B |
|---|---|
Previous open | 100.81 |
Previous close | 103.18 |
Incyte Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Incyte Corp Forecast
Price Target
By TipRanks
9.36% upside
12 Months Forecast
Average 110.06 USD 9.36%
High 135 USD
Low 75 USD
Based on 19 Wall Street analysts offering 12 month price targets forIncyte Corp - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Incyte Corp
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
